David A. Siegel Editas Medicine, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 940,600 shares of EDIT stock, worth $3.89 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
940,600
Previous 1,215,000
22.58%
Holding current value
$3.89 Million
Previous $1.41 Million
46.84%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding EDIT
# of Institutions
216Shares Held
45.4MCall Options Held
476KPut Options Held
338K-
Black Rock Inc. New York, NY7.78MShares$32.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$29.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.96MShares$8.13 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.88MShares$7.77 Million0.0% of portfolio
-
State Street Corp Boston, MA1.85MShares$7.65 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $285M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...